Dobutamine Hydrochloride

證據等級: L5

預測適應症: 0 個

Dobutamine Hydrochloride: Drug Repurposing Evaluation Report

One-Sentence Summary

Dobutamine hydrochloride is a synthetic catecholamine and beta-1 adrenergic agonist, widely used as a short-term inotropic agent for cardiac decompensation. The TxGNN model did not generate any predicted new indications for this drug, and the evidence pack contains significant data gaps across regulatory, safety, and mechanistic domains. This report serves as a data gap assessment to guide subsequent data collection.

Quick Overview

Item	Content
Original Indication	Not available in current dataset (known use: short-term inotropic support in cardiac decompensation)
Predicted New Indication	None — No TxGNN predictions generated
TxGNN Prediction Score	N/A
Evidence Level	L5 (No predictions or supporting studies)
Malaysia Market Status	✓ Marketed
Number of Registrations	4
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, the TxGNN model has not generated any repurposing candidates for dobutamine hydrochloride. This may be due to one or more of the following reasons:

Missing DrugBank ID mapping: The evidence pack shows drugbank_id: null. Without a valid DrugBank identifier, the drug cannot be properly anchored in the TxGNN knowledge graph, preventing the model from generating disease-association predictions. The query log indicates a DrugBank search was performed and returned 1 result, but the ID was not successfully linked to this record.
Narrow therapeutic profile: Dobutamine is a beta-1 selective adrenergic agonist primarily used as an intravenous inotrope for acute cardiac support. Its mechanism — stimulating cardiac contractility via beta-1 receptors — is highly specific and may have limited cross-disease applicability in the knowledge graph’s relational structure.
Data gaps in the evidence pack: The original MOA, approved indication text, and safety data are all missing, which limits the system’s ability to perform mechanistic reasoning and cross-indication inference.

Before drawing conclusions about dobutamine’s repurposing potential, the data gaps identified below must be resolved.

Malaysia Market Information

The evidence pack records 4 registrations for dobutamine hydrochloride with a market status of “Marketed.” However, detailed registration information (authorization numbers, product names, dosage forms, and approved indications) was not available in the current dataset.

Action needed: Retrieve full registration details from the NPRA database to populate this section.

Safety Considerations

Please refer to the package insert for safety information.

Note: The following critical data gaps were identified:

Key Warnings: Not available — TFDA/NPRA package insert data not yet parsed
Contraindications: Not available — package insert PDF download and parsing required
Drug Interactions: DrugBank DDI query returned no results (query status: not_found)

Data Gap Summary

The following blocking and high-severity data gaps must be addressed before this candidate can proceed through the evaluation pipeline:

Gap ID	Category	Item	Severity	Remediation
DG001	Drug Level	Package insert warnings/contraindications	Blocking	Download and parse package insert PDF from regulatory authority website
DG002	Drug Level	Mechanism of Action (MOA)	High	Query DrugBank API using INN “dobutamine”
—	Drug Level	DrugBank ID	High	Link the DrugBank search result (1 hit found) to this record
—	Prediction Level	TxGNN prediction	High	Re-run prediction pipeline after DrugBank ID is resolved
—	Regulatory Level	License details (authorization numbers, product names, indications)	Medium	Re-query NPRA with expanded fields

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN repurposing predictions were generated for dobutamine hydrochloride, primarily due to a missing DrugBank ID linkage that prevents knowledge graph integration. Additionally, multiple blocking data gaps in safety and regulatory information preclude any meaningful evaluation at this stage.

To proceed, the following is needed:

Resolve DrugBank ID mapping (the query log shows 1 result was found — confirm and link DB00841 for dobutamine)
Re-run the TxGNN prediction pipeline once the DrugBank ID is properly linked
Download and parse the package insert PDF to populate safety warnings and contraindications
Re-query NPRA to retrieve full license details (authorization numbers, product names, dosage forms, approved indications)
Once predictions are available, collect clinical trial and literature evidence for the top-ranked candidate indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.